12:00 AM
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Gilenya fingolimod regulatory update

The U.K.'s NICE issued draft guidance recommending against Gilenya fingolimod from Novartis to treat relapsing-remitting multiple sclerosis (RRMS). The committee said it could not determine how much Gilenya reduces the rate of relapses compared with available treatments because Novartis only submitted data comparing Gilenya with placebo and Avonex interferon beta-1a, which the agency said is not widely prescribed in the U.K.'s National Health Service....

Read the full 318 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >